FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL									
OMB Number:	3235-0104								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Novo A/S			2. Date of Ev Requiring Sta (Month/Day/Y 01/25/2017	itement 'ear)	3. Issuer Name and Ticker or Trading Symbol ANAPTYSBIO INC [ANAB]							
(Last) (First) (Middle) TUBORG HAVNEVEJ 19				Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)					
				Officer (give title below)	Other (spec		6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)						,	X	X Form filed by One Reporting Person				
HELLERUP ————————————————————————————————————	G7	2900						Form filed by Reporting Pe	More than One erson			
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownershi Form: Direc or Indirect (Instr. 5)	t (D) (Instr.	. Nature of Indirect Beneficial Ownership nstr. 5)					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)				
Series B Prefe	rred Stock		(1)	(1)	Common Stock	1,428,571(1)	(1)	D				
Series C Preferred Stock			(1)	(1)	Common Stock	486,820(1)	(1)	D				
Series C-1 Preferred Stock			(1)	(1)	Common Stock	312,986(1)	(1)	D				
Series D Preferred Stock			(1)	(1)	Common Stock	673,454 ⁽¹⁾	(1)	D				
Series C Preferred Stock Warrant (Right to Buy)			(2)	11/04/2018	Common Stock	117,235 ⁽²⁾	4.55	D				

Explanation of Responses:

1. The Series B Preferred Stock. Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock will automatically convert on a one-for-one basis for no additional consideration into common stock. The number of shares reported on this line item reflects the approximate number of shares of common stock subsequent to the 7-for-1 reverse split of common stock effected by the Issuer on January 13, 2017.

2. Immediately prior to the IPO Closing, the warrant will become exercisable for shares of common stock.

Remarks:

Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.

/s/ Peter Haahr, Chief Financial Officer of Novo A/S

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.